臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

About TAIR
	About TAIR

Browse By
	Institution
	Author
	Title
	Date
	Statistics Chart
	Institution Facts
	Trend

News
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

Copyright
	Publisher & Journal Policy
	TAIR Copyright Conference Minutes

Related Links
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"侯乃仁"

Return to Browse by Author
Sorting by Title	Sort by Date

Showing items 16-40 of 49 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page

Institution	Date	Title	Author
高雄醫學大學	2007	(在台灣慢性C型肝炎之肝臟脂肪變性及肝臟纖維化)	謝孟軒;李立柏;謝明彥;蔡坤寶;黃志富;侯乃仁;陳信成;林子堯;謝明裕;王良彥;戴嘉言;莊萬龍;余明隆 ; Hsieh MH;Lee LP;Hsieh MY;Tsai KB;Huang JF;Hou NJ;Chen SC;Lin ZY;Hsieh MY;Wang LY;Dai CY;Chuang WL;Yu ML
高雄醫學大學	2007	The HBV Infection Among Aboriginal Children 20 Years After Immunization In Taiwan	莊萬龍;余明隆;戴嘉言;何啟功;黃釧峰;侯乃仁;李立柏;謝明彥;黃志富;林子堯;陳信成;謝明裕;王良彥;張文宇
高雄醫學大學	2007	干安能治療B型肝炎引起失償非肝硬化病患早期死亡率及反應-以MELD及INDEX指標評估	戴嘉言;余明隆;侯乃仁;謝明彥;李立柏;黃志富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍
高雄醫學大學	2007	The antinuclear antibody is associated with lower RNA levels of hepatitis C virus and more advanced fibrosis in chronic hepatitis C patients	謝明彥;黃志富;侯乃仁;戴嘉言;李立柏;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍;余明隆
高雄醫學大學	2007	Almost all HCV G2 Pts With Rapid Virologic Response at Wk 4 Achieve a SVR With 16 Wks of Treatment	余明隆;戴嘉言;黃志富;侯乃仁;李立柏;謝明彥;丘長富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍
高雄醫學大學	2007	Different Features In Liver Histopathology Of HCV Monoinfection And HCV/HBV Dual Infection	李立柏;余明隆;戴嘉言;侯乃仁;謝明彥;林子堯;陳信成;謝明裕;王良彥;Chen, Tong-Jong;張文宇;莊萬龍
高雄醫學大學	2007	The Seroprevalence Of HBV And HCV Infection In Southern Taiwan- Large Scale Community-Based Study	莊萬龍;余明隆;戴嘉言;林嘉益;侯乃仁;李立柏;謝明彥;黃志富;謝明裕;張文宇
高雄醫學大學	2007	Transforming Growth Factor-Beta 1 Gene Polymorphisms In High Dose IFN/Ribavirin treated CHC Patients	戴嘉言;余明隆;張文宇;李立柏;潘文正;侯乃仁;謝明彥;黃志富;陳信成;林子堯;謝明裕;王良彥;莊萬龍
高雄醫學大學	2007	Early Mortality And Responses In Non-Cirrhotic Decompensated CHB Patients With Lamivudine Therapy	戴嘉言;余明隆;侯乃仁;謝明彥;李立柏;黃志富;陳信成;王良彥;張文宇;莊萬龍
高雄醫學大學	2007	EARLY MORTALITY AND RESPONSES IN NON-CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS B-RELATED DECOMPENSATION WITH LAMIVUDINE THERAPY: EVALUATION OF MELD AND INDEX SCORING SYSTEMS AS PROGNOSTIC PREDICTORS	戴嘉言;余明隆;侯乃仁;謝明彥;李立柏;黃志富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍
高雄醫學大學	2007	The presence of Antinuclear Antibody is associated with a negative response to combination therapy with peginterferon and ribavirin for patients without genotype 1 chronic hepatitis C infection	謝明彥;戴嘉言;黃志富;莊萬龍;侯乃仁;李立柏;陳信成;謝明裕;王良彥;張文宇;余明隆
高雄醫學大學	2007	High chance of cure in HCV genotype 1 patients with a low viral load achieving an RVR treated for 24 wks with pegylated interferon alfa-2a (PEGASYS) plus ribavirin (COPEGUS): Prospective, randomized, controlled study comparing 24 & 48 wks of treatm	余明隆;戴嘉言;黃志富;李立柏;謝明彥;丘長富;侯乃仁;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍*
高雄醫學大學	2006	Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy.	余明隆;戴嘉言;李立柏;謝明彥;侯乃仁;黃志富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍 ; Yu ML;Dai CY;Lee LP;Hsieh MY;Hou NJ;Huang JF;Lin ZY;Chen SC;Hsieh MY;Wang LY;Chang WY;Chuang WL
高雄醫學大學	2006	Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection.	戴嘉言;莊萬龍;張文宇;陳信成;李立柏;謝明彥;侯乃仁;林子堯;黃志富;謝明裕;王良彥;余明隆 ; Dai CY;Chuang WL;Chang WY;Chen SC;Lee LP;Hsieh MY;Hou NJ;Lin ZY;Huang JF;Hsieh MY;Wang LY;Yu ML
高雄醫學大學	2006	A randomized study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C	余明隆;戴嘉言;黃志富;侯乃仁;李立柏;謝明彥;丘長富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍
高雄醫學大學	2006	Predictors for early mortality in lamivudine-treated patients with chronic hepatitis B-related decompensation in Taiwan ”has been accepted for poster presentation at the forthcoming.	戴嘉言;莊萬龍;李立柏;謝明裕;侯乃仁;陳信成;林子堯;謝明彥;王良彥;黃志富;張文宇;余明隆
高雄醫學大學	2006	CLINICAL SIGNIFICANCE OF ERYTHROPOIETIN IN CHRONIC HEPATITIS C PATIENTS	侯乃仁;余明隆;戴嘉言;林子堯;張文宇;莊萬龍
高雄醫學大學	2006	A randomized, controlled, open-label study of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 vs. 24 weeks in patients with genotype 2 hepatitis C infection	余明隆;黃志富;侯乃仁;李立柏;謝明彥;丘長富;林子堯;陳信成;謝明彥;王良彥;張文宇;莊萬龍
高雄醫學大學	2006	Predictors for early mortality in lamivudine-treated patients with chronic hepatitis B-related decompensation in Taiwan ”has been accepted for poster presentation at the forthcoming.	戴嘉言;莊萬龍;李立柏;謝明裕;侯乃仁;陳信成;林子堯;謝明彥;王良彥;黃志富;張文宇;余明隆
高雄醫學大學	2005	Tumor necrosis factor alpha promoter polymorphism at position-308 predicts hepatitis C virus response to combination therapy with high dose interferon and ribavirin	戴嘉言;余明隆;莊萬龍;李立柏;謝明裕;侯乃仁;張文宇 ; Dai CY;Yu ML;Chuang WL;Lee LP;Hsieh MY;Hou NJ;Chang WY
高雄醫學大學	2005	甲型腫瘤壞死因子促動基因–308基因多型性與高劑量甲型干擾素合併ribavirin治療慢性C型肝炎療效之關聯	戴嘉言;余明隆;.莊萬龍;李立柏;謝明彥;侯乃仁;林子堯;陳信成;謝明裕;王良彥;蔡榮發;王良彥;蔡榮發;張文宇
高雄醫學大學	2005	感染基因型第二型之慢性C型肝炎病患以長效型干擾素合併Rivbavirin治療16及24週療程之比較:期中分析	戴嘉言;余明隆;李立柏;謝明彥;侯乃仁;黃志富;丘長富;林子堯;陳信成;謝明裕;王良彥;莊萬龍;張文宇
高雄醫學大學	2005	Polymorphisms in the Interferon-gamma gene at position +874 in patients with chronic Hepatitis C treated with high dose Interferon-Alpha and Ribavirin	戴嘉言;莊萬龍;張文宇;陳信成;李立柏;謝明彥;侯乃仁;林子堯;謝明裕;王良彥;余明隆
高雄醫學大學	2005	Tumor necrosis factor alpha promoter polymorphisms at position –308 predict hepatitis C virus response to combination therapy with high dose interferon and ribavirin	戴嘉言;余明隆;莊萬龍;李立柏;謝明彥;侯乃仁;王良彥;張文宇
高雄醫學大學	2004	The prevalence and clinical characteristics of coinfection of SENV-H among Taiwanese chronic hepatitis C patients with combination therapy of high-dose interferon-alfa and ribavirin.	戴嘉言;莊萬龍;張文宇;陳信成;李立柏;林子堯;侯乃仁;謝明裕;王良彥;余明隆 ; Chia-Yen Dai;Wan-Long Chuang;Wen-Yu Chang;Shinn-Cherng Chen;Li-Po Lee;Zu-Yau Lin;Nai-Jen Hou;Ming-Yuh Hsieh;Liang-Yen Wang;Ming-Lung Yu .

Showing items 16-40 of 49 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page

	English \| 正體中文 \| 简体中文 \| Total items :0
	Visitors : 52961782 Online Users : 973 Project Commissioned by the Ministry of Education Project Executed by National Taiwan University Library